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The Genetic Determination  
of Skin Pigmentation: KITLG and  
the KITLG/c-Kit Pathway as Key  
Players in the Onset of Human  
Familial Pigmentary Diseases
Mauro Picardo1 and Giorgia Cardinali1
Cutaneous pigmentation is regulated by a complex melanogenic network in 
which skin cells synthesize growth factors and cytokines. Mutations in genes 
encoding these regulators modify their expression and/or functionality, leading 
to altered signaling pathways and contributing to altered skin phenotypes. In this 
issue, Amyere et al. report a genome-wide analysis of seven families with familial 
progressive hyperpigmentation and hypopigmentation, identifying three new 
mutations in KITLG. The study underlines the relevance of investigating candidate 
genes implicated in the onset of pigmentary disorders. Furthermore, Amyere et al. 
suggest that different pigmentary diseases can result from the same mutation or 
different mutations in the same gene, and they offer hope for the development of 
new and efficacious treatment strategies.
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The control of constitutive and induced 
pigmentation is exerted by a complex 
paracrine network between mesen-
chymal and epithelial cells that regu-
lates melanocyte survival and function 
(Imokawa, 2004; Cario-André et al., 
2006; Yamaguchi and Hearing, 2009; 
Choi et al., 2010). Skin pigmentation is 
dependent on the type and amount of 
melanin, regulated by tyrosinase and 
tyrosinase-related enzyme activity and 
by other proteins responsible for the dif-
ferences in size, number, and distribution 
of melanosomes within keratinocytes 
(Alaluf et al., 2003). Keratinocytes pro-
duce cytokines and growth factors that 
support melanogenesis; these include 
endothelin-1, α-melanocyte-stimulating 
hormone, and basic fibroblast growth 
factor, which are involved mainly in 
UVB-induced pigmentation (Imokawa, 
2004). Experimental evidence supports 
a role for dermal cells in melanocyte 
function and skin pigmentation. In par-
ticular, the c-Kit ligand (KITLG) influ-
ences melanocyte proliferation and 
melanin distribution and activates kera-
tinocytes to produce promelanogenic 
factors (Cario-André et al., 2006), and 
keratinocyte growth factor promotes 
melanosome phagocytosis (Cardinali et 
al., 2005, 2008) (Figure 1). Fibroblasts 
have a role in pathological pigmenta-
tion, and an altered expression of vari-
ous growth factors has been implicated 
in UVB melanosis (Hachiya et al., 2001), 
lentigo senilis (Chen et al., 2010; Kovacs 
et al., 2010), melasma (Kang et al., 2006; 
Imokawa, 2004), seborrhoeic keratosis 
(Manaka et al., 2001), dermatofibroma 
(Shishido et al., 2001), and familial pro-
gressive hyperpigmentation-like disorder 
(Cardinali et al., 2009). Mutations in the 
encoding genes could be the basis for 
some of these diseases. For this reason, 
many investigators have recently focused 
their research on the identification of 
candidate genes for the control of skin 
pigmentation.
the identification of genes causing 
pigmentary diseases: a genetic approach 
to understanding the molecular 
mechanisms of pigmentation
Several genes regulate the pigmenta-
tion process, and the onset of patho-
logical conditions can be related to the 
presence of mutations resulting in clini-
cal variations of a disease. In this issue, 
Amyere et al. (2011) used genome-wide 
linkage analysis to identify mutations 
that lie within the intracellular tyrosine 
kinase domain of the KITLG gene in 
seven families with familial progressive 
hyperpigmentation and hypopigmenta-
tion (FPHH). FPHH is characterized by 
diffuse, progressive skin hyperpigmenta-
tion that begins at an early age; FPHH is 
also associated with café-au-lait macules 
(CALMs) and generalized lentiginosis 
intermixed with larger hypopigmented 
ash-leaf macules. Histologically, hyper-
pigmented areas exhibit normal epider-
mis with strongly hyperpigmented basal 
keratinocytes and melanophages in the 
upper dermis. The absence of systemic 
symptoms and signs suggests a patho-
genesis related to melanogenesis. KITLG 
has a crucial role in melanocyte develop-
ment and melanin synthesis in mammals, 
although its expression varies among 
species. In this study Amyere et al. (2011) 
identified a linkage on 12q21.12–q22 
and a KITLG mutation in four families. 
Three mutations in KITLG cosegregated 
in four families: a c.107A>G mutation 
was found in two families (also reported 
for a Chinese family and two other muta-
tions); and c.98T>C and c.100A>C sub-
stitutions were identified in the two other 
families. The absence of mutations in the 
remaining three families could be related 
to a recessive inheritance or dominant 
inheritance with reduced penetrance or 
X-linked inheritance. Analysis of the sec-
ondary structure of KITLG identified the 
three mutations in the third b-strand of 
KITLG as responsible for weakened affin-
ity of the ligand to its c-Kit receptor. All 
four amino acid substitutions localized 
in a conserved sequence of VTNN, 
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causing a gain of function of KITLG that 
increases affinity to the c-Kit receptor. 
Previous pedigree analysis of three fami-
lies clustered in southeastern Germany 
presenting with FPHH associated with 
generalized lentiginosis suggested an 
autosomal dominant pattern of inheri-
tance with variable expression and 
reduced penetrance.
The investigators did not exclude 
a common origin of the phenotype, 
perhaps by the same mutation. A 
genome-wide scan for linkage analy-
sis in a six-generation Chinese family 
affected by familial progressive hyper-
pigmentation (FPH) (Wang et al., 2010) 
identified two loci: 19p13–pter and 
12q21.31–q23.1. The mutation profil-
ing at the locus mapped at chromosome 
12q21.31–q23.1 detected a transver-
sion (c.107A>G) in exon 2 of KITLG, 
which is reflected in the substitution 
of a serine for an asparagine residue at 
codon 36 (p.N36S). This mutation is 
responsible for inherited FPH, produc-
ing a gain-of-function defect in tyrosi-
nase activity and melanin synthesis. The 
same mutation (p.Asn36Ser) found in 
FPHH has been related to FPH, suggest-
ing that the hyperpigmented phenotype 
could depend on environmental factors. 
Among the pigmentation disorders that 
must be differentiated from FPHH are 
the dyschromatoses, a group of disor-
ders characterized by the simultaneous 
presence of hyper- and hypopigmenta-
tion in variable distribution and patterns. 
Dyschromatosis symmetrica hereditaria 
(DSH) and dyschromatosis universalis 
hereditaria (DUH) are two major forms. 
Both conditions mainly have an auto-
somal dominant mode of inheritance, 
and the gene locus for DSH was mapped 
to chromosome 6q24.2–q25.2 or 1q11–
1q21 in Chinese families (Wang et al., 
2010; Pan et al., 2010). However, an 
Arabic family with DUH in two sepa-
rate generations has been reported, sug-
gesting an autosomal recessive mode 
of inheritance (Bukhari et al., 2006). 
Furthermore, other studies indicate a 
varied expression of DUH, including 
atypical morphologic presentation, the 
involvement or the exclusion of system-
ic symptoms, and the predominance of 
lesions in sun-exposed areas of the skin 
(Dhaoui and Doss, 2001). It is interesting 
to note that DUH2, phenotypically and 
histologically similar to FPH, is also 
linked to 12q21.31–q23.1 (Stuhrmann 
et al., 2008).
Considering the importance of the 
KITLG/c-Kit pathway in regulating pig-
mentation, not only KITLG mutations 
but also mutations in genes encoding 
for c-Kit or regulators of the RAS/MAPK 
pathway must be considered in the anal-
ysis of severe pigmentation phenotypes. 
Piebaldism, an autosomal dominant 
disorder caused by altered melanoblast 
proliferation and migration, has been 
associated with mutations in the c-Kit 
gene. A novel missense mutation in exon 
12 (c.1833A>C) that causes a substitu-
tion at codon 611 (p.Leu611Phe) result-
ing in a mild piebald phenotype has 
been found recently (Chong et al., 2010), 
underscoring the notion that different 
mutations in the same gene can result in 
a range of disease severity.
Germline mutations in the neuro-
fibromatosis type 1 (NF1) tumor sup-
pressor gene (which encodes for 
neurofibromin, a positive regulator of 
RAS) have been identified in NF1, an 
autosomal dominant condition char-
acterized by multiple CALMs, axillary 
freckling, Lisch nodules in the iris, and 
tumors of the nervous system. An addi-
tional NF1 mutation was demonstrated 
in CALM-derived melanocyte cultures 
(De Schepper et al., 2008), indicating 
that apart from the germline mutation, 
second-hit mutations in NF1, which 
occur more frequently in CALM mel-
anocytes, are needed to form CALMs 
and to initiate tumor formation. The 
Legius syndrome, an NF1-like phe-
notype characterized by the presence 
of CALMs without neurofibromas, is 
caused by a germline loss-of-function 
mutation in SPRED1 (Brems et al., 
2007). Spreds form a protein fam-
ily with an N-terminal enabled/VASP 
homology 1 domain (EVH1), a central 
c-Kit binding domain, and a c-terminal 
Sprouty-related domain. These proteins 
are able to inhibit the Ras/MAPK signal-
ing pathway after mitogenic stimulation. 
Murine Spred-1 is tyrosine phosphory-
lated by SCF (Bundschu et al., 2007).
Analysis of the genetic determinants 
of hair and eye colors in the Scottish 
and Danish populations (Mengel-From 
et al., 2009) by genotyping DNA at 
single-nucleotide polymorphisms (SNPs) 
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Figure 1. the control of skin pigmentation is exerted by a complex melanogenic paracrine network 
between mesenchymal and epithelial cells, which regulates melanocyte survival, proliferation, and 
melanogenesis. Among melanogenic growth factors, KITLG and its receptor c-Kit triggering Ras/MAPK 
signaling pathway play crucial roles in the control of physiological and pathological skin pigmentation. 
α-MSH, α-melanocyte stimulating hormone; bFGF, basic fibroblast growth factor; C-Met, receptor for 
HGF; ERK, extracellular signal-related kinases; ET-1, endothelin-1; ETBR, endothelin B receptor; FGFR2, 
fibroblast growth factor receptor 2; HGF, hepatocyte growth factor; KGF, keratinocyte growth factor; 
KGFR, keratinocyte growth factor receptor; MC1R, melanocortin-1 receptor; MEK, mitogen-activated 
kinase kinase; POMC, proopiomelanocortin.
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in 33 candidate genes confirmed that 
MC1R, the specific G-protein-coupled 
receptor for α-melanocyte-stimulating 
hormone, correlates with red hair. 
However, a significant association of hair 
color with KITLG and the oculo albinism 
2 (OCA2) gene (which codifies for a trans-
porter protein localized to the melano-
some) was also found, further confirming 
the relevance of the KITLG/c-Kit pathway 
in controlling skin pigmentation.
The role of fibroblast-derived 
growth factors in skin pigmenta-
tion disorders is further supported 
by studies on solar lentigo. The 
disorder appears to result from UV 
radiation–induced upregulation 
of genes related to melanogen-
esis (for example, genes for tyro-
sinase and tyrosinase-related pro-
tein 1), together with those related 
to chronic inflammation and fatty 
acid metabolism (Aoki et al., 2007). 
A slight upregulation of KITLG, 
α-melanocyte-stimulating hormone, 
endothelin-1, and their receptors as 
well as of HGF, keratinocyte growth 
factor, and SCF has been demon-
strated in the upper dermis of solar 
lentigo lesions. The mRNA of these 
cytokines was induced in an in vitro 
model of photoaged fibroblasts, 
suggesting that chronic UV expo-
sure could activate fibroblasts to 
release melano genic growth factors 
that contribute to hyperpigment-
ation (Kovacs et al., 2010).
concluding remarks
Cutaneous pigmentation is regulated by a 
complex melanogenic network in which 
skin cells synthesize growth factors and 
cytokines. The mechanisms underlying the 
development of altered skin phenotypes 
are not completely defined. Moreover, 
for many genetic disorders a strong 
variability in penetrance and expres-
sion has been assumed. The study by 
Amyere et al. (2011) represents an impor-
tant contribution to the field of genome-
wide linkage analysis. Their results will 
enhance understanding of the molecular 
mechanisms, which, starting from altered 
expression and/or functionality of mela-
nogenic factors and their receptors, lead 
to altered signaling pathways responsible 
for pigmentary diseases.
In particular, the KITLG/c-Kit and Ras/
MAPK pathways were identified as cru-
cial points for controlling pigmentation. 
Moreover, the results underline the likeli-
hood that different pigmentary disorders 
can result from the same mutation or dif-
ferent mutations in the same gene and 
that environmental factors may influence 
disease phenotype.
These studies provide important clues 
for understanding the molecular mech-
anisms of pigmentation, and they may 
increase our ability to develop effective 
intervention strategies for pigmentary 
disorders.
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Clinical Implications
•  Cutaneous pigmentation is regulated by a complex melanogenic network 
of cells that elaborate growth factors and cytokines.
•  In many disorders of pigmentation, there is considerable variability in 
penetrance and expression of the relevant genes, complicating the analysis.
•  The study by Amyere et al. (2011) identifies the KITLG/c-Kit and Ras/MAPK 
pathways as crucial points in controlling pigmentation.
•  These clues in understanding the molecular mechanisms of pigmentation 
may lead to effective therapies.
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More than 25 years ago, Nordlund et 
al. reported six patients with spreading 
vitiligo treated with applications of 
monobenzone who subsequently devel-
oped a vesicular dermatitis (Nordlund 
et al., 1985). Interestingly, the eruption 
was restricted to the pigmented areas of 
the skin. Patch tests applied to pigment-
ed and depigmented skin produced 
inflammatory responses only within 
the pigmented areas, indicating that the 
effect depends on the presence of mel-
anocytes. In this issue, van den Boorn 
et al. provide an explanation for this 
puzzling phenomenon (Figure 1).
Application of monobenzone induces 
local depigmentation within 2 weeks, 
extending within a few months, however, 
to nonexposed skin sites. This observation 
indicates that monobenzone-induced 
depigment ation is not only based on 
direct effects on melanocytes but also 
involves a systemic process. Histological 
examination of biopsies obtained from 
monobenzone-treated skin revealed 
CD8+ T-cell infiltrates similar to those 
observed in spontaneous vitiligo or 
melanoma-associated hypopigmentation 
(Hartmann et al., 2008), thereby provid-
ing the first clue that the systemic effect 
probably results from an immunological 
process.
The direct effect of monobenzone 
is attributed to inhibition of tyrosinase 
activity. Indeed, van den Boorn et al. 
(2011, this issue) demonstrated that tyro-
sinase metabolized monobenzone to 
4-benzoxy-1,2-benzoquinone, which in 
turn inactivates tyrosinase by formation 
of quinone hapten binding to tyrosinase 
cysteine residues. Thus, monobenzone 
exposure reduces pigment-cell melano-
genesis without exerting selective toxicity. 
Notably, reactive benzene metabolites 
such as quinones are effective contact 
sensitizers, binding to proteins and form-
ing hapten–carrier complexes that trig-
ger hapten-specific immune responses 
(Ezendam et al., 2003). Consequently, 
van den Boorn et al. investigated the 
effects of mono benzone on the immuno-
genicity of pigmented cells, i.e., melano-
cytes and melanoma cells. Exposure to 
monobenzone induced reactive oxygen 
species exclusively in pigmented cells, 
associated with an increased release 
of tyrosinase- and MART-1-containing 
CD63+ exosomes. Exosomes are known 
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Breaking Immunological Tolerance  
to Melanocyte Differentiation 
Antigens by Hypopigmenting  
Agents: A new Means for  
Melanoma Immunotherapy?
Jürgen C. Becker1 and David Schrama1
The hypopigmenting agent monobenzone induces inflammatory responses only 
in pigmented skin as well as depigmentation in areas not directly exposed to the 
drug. Both observations have been ascribed to the possible induction of adap-
tive immune responses against melanocytes. In this issue, van den Boorn et al. 
provide direct evidence confirming this hypothesis. Since the monobenzone-
induced immune responses target melanocyte-differentiation antigens, this 
report opens the opportunity for a simple and instantaneous deployable 
immuno therapy of melanoma.
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Skin pigmentation depends primar-
ily on the amount and type of melanin 
synthesized by melanocytes located in 
the basal layer of the epidermis and its 
distribution toward the surface of the 
epidermis (Yamaguchi et al., 2007). 
Melanin is synthesized within a spe-
cialized organelle, the melanosome. 
The essential enzyme in its synthesis is 
tyrosinase, a melanosomal membrane 
glycoprotein that catalyzes the initial 
and rate-limiting steps of melano-
genesis. Ultimately, melanin packed 
in melanosomes is transferred from the 
melanocytes to adjacent keratinocytes.
Agents to control skin pigmentation 
are used to address a variety of medical 
conditions, such as acquired hyperpig-
mentation and vitiligo (Hartmann et al., 
2004). Hypopigmenting agents include 
hydroquinone or its monobenzyl ether, 
monobenzone (Solano et al., 2006); the 
drug Benoquin, manufactured by ICN, 
contains 20% monobenzone. 
Mengel-From J, Wong TH, Morling N et al. (2009) 
Genetic determinants of hair and eye colours 
in the Scottish and Danish populations. BMC 
Genet 10:88
Pan H, Wang Z, He B et al. (2010) Identification 
of a novel mutation in the DSRAD gene in a 
Chinese family with dyschromatosis symmetrica 
hereditaria. J Am Acad Dermatol 63:529–30
Shishido E, Kadono S, Manaka I et al. (2001) The 
mechanism of epidermal hyperpigmentation 
in dermatofibroma is associated with stem cell 
factor and hepatocyte growth factor expression. 
J Invest Dermatol 117:627–33
Stuhrmann M, Hennies HC, Bukhari IA et 
al. (2008) Dyschromatosis universalis 
hereditaria: evidence for autosomal recessive 
inheritance and identification of a new locus 
on chromosome 12q21–q23. Clin Genet 
73:566–72
Wang XP, Liu Y, Wang JM et al. (2010) Two novel 
splice site mutations of the ADAR1 gene 
in Chinese families with dyschromatosis 
symmetrica hereditaria. J Dermatol 37:1051–2
Yamaguchi Y, Hearing VJ (2009) Physiological 
factors that regulate skin pigmentation. 
Biofactors 35:193–9
